In the first half of the year, AIM Vaccine actively promoted the development of the vaccine product pipeline according to the established strategy, and through continuous technological innovation, rapidly promoted the R&D of the iteratively upgraded pneumonia vaccine series, accelerating the realization of new quality production forces. On August 29, AIM Vaccine (06660.HK) released the performance for the first half of 2024. Financial data shows that in the first half of this year, AIM Vaccine recorded revenue of 537 million yuan, which was basically the same as the same period last year, and the loss was significantly reduced.

On August 29, the Hong Kong-listed company AIM Vaccine (06660.HK) announced that the company had submitted pre-applications for clinical trials of mRNA RSV (respiratory syncytial virus) vaccine and mRNA shingles vaccine to the U.S. Food and Drug Administration (FDA) for the first time in August 2024. Prior to this, pre-clinical trial applications had been submitted to the Center for Drug Evaluation(CDE), NMPA in June 2024. This is an important step for AIM Vaccine to enter the international market with blockbuster innovative single-item vaccines.

On August 29, AIM Vaccine (06660.HK) disclosed the semi-annual report and the latest developments of several blockbuster single-item products. Among them, aiming at the international market, AIM has submitted a pre-application for clinical trials of mRNA RSV (respiratory syncytial virus) vaccine and mRNA shingles vaccine to the U.S. Food and Drug Administration (FDA) for the first time in August 2024. Prior to this, these two mRNA vaccine products have shown good data compared to marketed control vaccines in animal tests, and a pre-application for clinical trials was submitted to the Center for Drug Evaluation (CDE), NMPA in June 2024.

According to AIM Vaccine (06660.HK), Vice President and Chief Research Officer Zhang Fan, and General Manager of AIM Lifanda Peng Yucai, recently published the preclinical research data of the mRNA rabies vaccine LVRNA001 in the international authoritative academic journal "npj Vaccines": Only two vaccinations are needed to provide 100% safe and effective immune protection. This has laid a solid foundation for the next stage of research on human rabies mRNA vaccines.

From a "cold edge" technology to large-scale commercial application, a new chapter of medicine belonging to mRNA therapy has opened. In the post-epidemic era, the mRNA technology platform, which has become famous due to COVID-19 vaccines, is showing more and more possibilities for drug development.

Amy Vaccine had submitted a pre-application for clinical trials of respiratory syncytial virus (RSV) mRNA vaccine and shingles mRNA vaccine to the Center for Drug Evaluation, NMPA. Amy Vaccine stated that this is a new innovative progress the company has achieved after the development of rabies mRNA vaccine.